Anti-Tenascin C monoclonal antibody, clone 6819

Nanocomposite modifiers reinforce the whole characteristics of epoxy coatings for different steel surface applications. To support this concept, sol-gel synthesized TiO2 nanoparticles (TNPs) were mixed with nonylphenol ethoxylate (NPhE) to form nonylphenol ethoxylate/TiO2 nanocomposite (NPhE/TNC) as a modifier for epoxy coating applied on the C-steel surface. TNPs were characterized by XRD, SEM and HR-TEM techniques. Various modified NPhE/TNC epoxy coating formulations with different loading levels (0.5, 1, 1.5, 2 and 2.5%) by weight were prepared. FT-IR spectra were used for characterizing of the formed nanocomposites. The anti-corrosion behavior of surface-modified NPhE/TNC coated films versus unmodified conventional epoxy was studied by salt spray accelerated corrosion test. The obtained results demonstrated a considerable improvement in the rust grade, blistering size and frequency, and adhesion strength of modified NPhE/TNC epoxy nanocomposite coated films and affirmed by SEM morphology survey. The impact resistances of unmodified and modified NPhE/TNC epoxy coatings were measured where the best impact resistance was recorded for NPhE/TENC-E coated film at 51 J. Acids and alkali chemical immersion test was performed to check the chemical immovability for the surface-modified NPhE/TNC coated films against conventional epoxy where NPhE/TENC-E coating showed the suitable immovability levels.

BackgroundExtracellular matrix proteins tenascin-C (TNC) and periostin, which were identified as T-helper cell type 2 cytokine-induced genes in human bronchial epithelial cells, accumulate in the airway basement membrane of asthmatic patients. Although serum periostin has been accepted as a type 2 biomarker, serum TNC has not been evaluated as a systemic biomarker in asthma. Therefore, the objective of this study was to evaluate whether serum TNC can serve as a novel biomarker for asthma.MethodsWe evaluated 126 adult patients with mild to severe asthma. Serum TNC, periostin, and total IgE concentrations were quantified using enzyme-linked immunosorbent assays.ResultsSerum TNC levels were significantly higher in patients with severe asthma and high serum total IgE levels. Patients with both high serum TNC (>37.16ng/mL) and high serum periostin (>95ng/mL) levels (n=20) or patients with both high serum TNC and high serum total IgE (>100IU/mL) levels (n=36) presented higher disease severity and more severe airflow limitation than patients in other subpopulations.ConclusionsTo our knowledge, this is the first study to show that serum TNC levels in asthmatic patients are associated with clinical features of asthma and that the combination of serum TNC and periostin levels or combination of serum TNC and total IgE levels were more useful for asthma than each single marker, suggesting that serum TNC can serve as a novel biomarker for asthma.